Pulse Biosciences, Inc. (PLSE)

NASDAQ: PLSE · Real-Time Price · USD
15.08
+0.55 (3.79%)
At close: Apr 4, 2025, 4:00 PM
15.96
+0.88 (5.82%)
After-hours: Apr 4, 2025, 7:56 PM EDT
3.79%
Market Cap 1.01B
Revenue (ttm) n/a
Net Income (ttm) -53.59M
Shares Out 67.27M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 250,112
Open 14.05
Previous Close 14.53
Day's Range 13.93 - 15.18
52-Week Range 6.60 - 25.00
Beta 1.88
Analysts n/a
Price Target n/a
Earnings Date May 6, 2025

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporat... [Read more]

Sector Healthcare
IPO Date May 18, 2016
Employees 56
Stock Exchange NASDAQ
Ticker Symbol PLSE
Full Company Profile

Financial Performance

Financial Statements

News

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer...

8 days ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

9 days ago - Business Wire

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

10 days ago - Business Wire

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

4 weeks ago - Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today...

4 weeks ago - Business Wire

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans...

6 weeks ago - Business Wire

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA ...

2 months ago - Business Wire

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced ...

2 months ago - Business Wire

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking ...

2 months ago - Business Wire

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA tec...

2 months ago - Business Wire

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsP...

3 months ago - Business Wire

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans ...

3 months ago - Business Wire

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...

3 months ago - Business Wire

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano...

3 months ago - Business Wire

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new ...

3 months ago - Business Wire

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positi...

5 months ago - Business Wire

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Of...

5 months ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-P...

5 months ago - Business Wire

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of...

5 months ago - Business Wire

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report fin...

5 months ago - Business Wire

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Pulse Biosciences Inc. (NASDAQ:PLSE) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffle...

8 months ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) techn...

8 months ago - Business Wire

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

8 months ago - Business Wire

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

8 months ago - Business Wire

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

8 months ago - Business Wire